Company: CYTK
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001193125-25-039426
Chunk: 40

Company: CYTOKINETICS INC
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 40
---
 filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We also incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC:

We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K andexhibits filed on such form that are related to such items unless such Form 8-K expresslyprovides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus and will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have “furnished” to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus. We will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to: Cytokinetics, Incorporated 350 Oyster Point Boulevard South San Francisco, California 94080 United States of America Attn: Investor Relations (650) 624-3000 30

PROSPECTUS SUPPLEMENT

Up to $500,000,000

Common Stock

We have entered
into an Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, dated February 27, 2025, relating to the sale of shares of our common stock, $0.001 par value
per share. In accordance